Remarks

Support for the foregoing amendment to the claims and new claims may be found throughout the specification and claims as originally filed, either inherently or explicitly. Support for the amendment to claim 36 may be found in the specification at pages 15, 21 and throughout the examples. Support for the new claims 69 and 70 may be found in the specification at pages 22, 24 and throughout the examples. None of the foregoing amendments adds new matter. Accordingly, Applicants respectfully request that the foregoing amendments be entered and considered.

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Andrea Jo Kamage

Andrea Jo Kamage
Agent for Applicants
Registration No. 43,703

Date: 12/21/01

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

(a) Claims 69-70 are added.

(b) Claim 36 is amended as follows:

36. (Twice amended) A tumor vaccine for administration to a patient, wherein said tumor vaccine comprises tumor cells which present a first set of peptides in an HLA context, wherein said first set of peptides are derived from tumor antigens, and wherein at least some of said tumor cells have at least one MHC-I haplotype of said patient on the cell surface, and wherein said tumor cells further comprise a second set of peptides which bind the peptide binding fork of said MHC-I haplotype and wherein said second set of peptides are selected from the group consisting of:

(a) peptides which are different from peptides which are derived from proteins expressed by the cells of said patient; and

(b) peptides which are derived from tumor antigens which are expressed by said patient's cells and are present at a higher concentration on said tumor cells of said vaccine than on said patient's cells;

and wherein said tumor cells have been incubated in the presence of an organic polycation with one or more said peptides (a) or (b) or both (a) and (b) in such a way that said tumor cells are recognized as foreign by the immune system of said patient and trigger a cellular immune response in said patient;

and wherein said organic polycation is selected from the group consisting of polylysine, polyarginine, polyornithine, polyethyleneimines, histones, protamines, spermine and spermidines;

and wherein said tumor cells have not been transfected with DNA coding for said second set of peptides.